Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-α (IFN-α).
Emma Hitt, PhD
Advertisement
Articles by Emma Hitt, PhD
Heinz-Josef Lenz, MD, has focused his research on a range of scientific and translational questions, including the regulation of gene expression in drug resistance and targeted therapies.
Tumor-initiating cells are thought to be the source of metastasis. For these reasons, the Wnt pathway is viewed as a strong candidate for therapeutic intervention.
The clinical subtyping of breast cancer appears to be coming into a golden era as an increased understanding of subtyping promises to help advance treatments and outcomes for patients.
Advertisement
Latest Updated Articles
Subtyping Breast Cancer: Genome Analysis Opens Door to New Era in Targeted TherapiesPublished: December 4th 2012 | Updated:
Wnt Signaling Inhibition: Will Decades of Effort Be Fruitful at Last?Published: January 7th 2013 | Updated:
Five Wnt-Related Questions for Heinz-Josef Lenz, MDPublished: January 7th 2013 | Updated:
Novel Agents Revolutionize Melanoma TreatmentPublished: September 5th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5